Floatz logo

AVN-944

Chronic Leukemia

Vertex Pharmaceuticals IncorporatedSmall moleculePhase 1Dormant
CC
42/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
27/ 100
Competitive Position
95/ 100

Competitive context

5 Active assets in the Chronic Leukemia cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
Roswell Park Cancer Institute
Phase 4BB
Busulphan
University of Rochester
Phase 4B
IMMUNOGLOBULIN G1 (HUMAN-RAT MONOCLONAL CAMPATH-1H .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD52), DISULFIDE WITH HUMAN-RAT MONOCLONAL CAMPATH-1H LIGHT CHAIN, DIMER
Steven E. Coutre
Phase 2B
p.DOM-WT1-126 DNA Vaccine
University Hospital Southampton NHS Foundation Trust
Phase 2B
Fludarabine
Roswell Park Cancer Institute
Phase 2B

View all 12 →

Same molecule, other indications

AVN-944 is also rated in:

pancreatic neoplasmDormant
CC
Indicative ·
42 / 100
View asset →
Hodgkins lymphomaDormant
CC
Indicative ·
42 / 100
View asset →
Waldenstrom macroglobulinemiaDormant
CC
Indicative ·
42 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →